Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
SZSE:301033'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.58 Med: 16.65 Max: 30.96
Current: 13.08
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Medprin Regenerative Medical Technologies Co was 30.96. The lowest was 12.58. And the median was 16.65.
SZSE:301033's Price-to-Net-Current-Asset-Value is ranked worse than 78.55% of 564
companies
in the Medical Devices & Instruments industry
Industry Median: 4.885
vs SZSE:301033: 13.08
Medprin Regenerative Medical Technologies Co (SZSE:301033) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Medprin Regenerative Medical Technologies Co Net Current Asset Value Related Terms
Medprin Regenerative Medical Technologies Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co Net Current Asset Value Chart
Medprin Regenerative Medical Technologies Co Annual Data
SZSE:301033 vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Medprin Regenerative Medical Technologies Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medprin Regenerative Medical Technologies Co Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medprin Regenerative Medical Technologies Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Medprin Regenerative Medical Technologies Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥4.65 mean?
Medprin Regenerative Medical Technologies Co (SZSE:301033) has a Net Current Asset Value of ¥4.65 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. According to the industry distribution chart, Medprin Regenerative Medical Technologies Co ranks #443 out of 564 companies in the Medical Devices & Instruments industry, placing it in the top 78.5%.
Is Medprin Regenerative Medical Technologies Co's Net Current Asset Value too high?
Medprin Regenerative Medical Technologies Co's current Net Current Asset Value is ¥4.65. Based on the distribution chart, Medprin Regenerative Medical Technologies Co ranks #443 out of 564 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medprin Regenerative Medical Technologies Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medprin Regenerative Medical Technologies Co's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medprin Regenerative Medical Technologies Co ranks #443 out of 564 companies for Net Current Asset Value. This places Medprin Regenerative Medical Technologies Co in the lower half of its industry. The industry median Net Current Asset Value is 4.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.89, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medprin Regenerative Medical Technologies Co's current Net Current Asset Value is ¥4.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medprin Regenerative Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co (SZSE:301033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥73.38, compared to a current price of ¥52.96 — trading 27.8% below its estimated fair value. The current Net Current Asset Value is ¥4.65. Medprin Regenerative Medical Technologies Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Medprin Regenerative Medical Technologies Co (SZSE:301033), the current Net Current Asset Value is ¥4.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medprin Regenerative Medical Technologies Co (SZSE:301033) Overvalued in 2026?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co stock appears to be undervalued.
The current stock price of ¥52.96 is trading 27.8% below its estimated GF Value™ of ¥73.38.
GuruFocus considers Medprin Regenerative Medical Technologies Co to be Modestly Undervalued.
Key valuation signals for SZSE:301033:
Net Current Asset Value: ¥4.65
GF Value™: ¥73.38 vs. price of ¥52.96 (27.8% below fair value)
No single metric tells the full story. See the SZSE:301033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301033 has been successfully added to your 
